Future Market Insights (FMI) in its market analysis projects the parenteral packaging market to grow at 5.5% CAGR during the forecast period 2021-2031. Driven by the rising necessity of effective packaging solutions for therapeutic drugs without compromising their potency, the parenteral packaging market is forecast to reach the market valuation of US$ 11,460 Mn in 2021.
North America is expected to provide lucrative growth opportunities backed by increasing healthcare spending and rising production rate of parenteral packaging in U.S. Spurred by this, the North America parenteral packaging worth is projected to expand at 4.3% CAGR in 2021.
Parenteral Packaging Market Outlook
The parenteral packaging market is anticipated to witness a positive growth trajectory, however, several factors such as instability in the price of raw materials and limited availability of raw materials are expected to hinder the growth of the parenteral packaging market. Additionally, the complex registration process of packaging is likely to be a constraint in the parenteral packaging market expansion.
Key players are focusing on providing an extensive scope of packaging materials for parenteral drugs. For example,
Gerresheimer, a market leader in the manufacturing of cosmetics packaging prepared of recycled glass, in response to its customers developed a cosmetics glass that has the utmost recycled material proportion available for the end consumer and simultaneously provides an incomparable level of quality.
The company, further initiated two more plants in India and China for pharmaceutical products, to produce plastic primary packaging. This will allow it to offer its consumer, the best possible supply service.
Bormioli Pharma, a manufacturer of plastic primary and pharmaceutical glass packaging, acquired GCL Pharma, an Italian subsidiary of the Guala Closures Group, focused on the manufacturing of aluminum, rubber, and plastic closures for pharmaceutical applications. This follows Bormioli’s purchase of Remy & Geiser finished last fall, growing its ability and product range to support the most difficult pharmaceutical requirements.
Bormioli Pharma focuses to fortify its industrial footprint by adding novel technologies that will allow them to extend their product range, particularly in the parenteral and oral segments, further stimulating their business synergies.
The significance of packaging in the pharma industry to strike an accurate balance between regulatory compliance, quality, and cost is an established fact. Thus, as the pharma sector dynamics get transformed by the COVID-19 pandemic it is apparent that pharma labeling and packaging too will undertake major shifts.
The future embraces unparalleled challenges and opportunities in terms of labeling and the pharma packaging sector. The sector will have to evolve continually to meet the pharma stakeholders’ expectations, combating counterfeits, be it assuring efficacy of medicines, enabling patient convenience and adherence, upkeep logistics security, or following to regulatory requirements.
Drivers & Restraints
Some of the key drivers for the growth of the global parenteral packaging market include the increasing per capita healthcare expenditure of several leading economies across the globe. Parenteral drugs is the second-largest contributor to the global pharmaceutical market of US$ 962 Billion, with approximately 30% share in 2014, preceded only by oral dosage form.
Moreover, the long-term estimates that pharma spending is expected to match the expenditure on healthcare sector at an average of 4.2% during the forecast period. Additionally, private health insurance (PHI) are playing significant role in carving up the healthcare systems.
The overall impact of rise in per capita expenditure and introduction of health insurance are expected to favor the growth of parenteral packaging market.
Immunizations through vaccines are a major health intervention that has a significant positive impact on the health the populace. Demand for parenteral is strongly correlated with immunization.
Vaccination plans such as Global Vaccine Action Plan (GVAP) 2011–2020, National Vaccine Plan (NVP) by U.S., which are introduced by the government on regular intervals to eradicate health issues such as hepatitis, polio etc., are expected to further fuel the parenteral packaging market.
According to World Health Organization (WHO) chronic non-communicable disease (NCD) prevalence is projected to grow by 57% between 2015 and 2020. In terms of geographical inclination of demand, emerging markets are expected to contribute significantly to growth, largely due to diseases related to lifestyle changes as well as population increase.
Competitive Landscape
Key players operating in the global market for parenteral packaging include UFP Technologies, Inc., Schott AG, UDG Healthcare plc, Gerresheimer AG, Becton, Dickinson and Company, Catalent, Inc., Stevanato Group S.p.A., Baxter International Inc., Nipro Corporation, West Pharmaceutical Services, Inc., among others among others.
